Cite
Wasel N, Thaçi D, French LE, et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663-670doi: 10.1007/s13555-020-00383-x.
Wasel, N., Thaçi, D., French, L. E., Conrad, C., Dutronc, Y., Gallo, G., Berggren, L., & Lacour, J. P. (2020). Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatology and therapy, 10(4), 663-670. https://doi.org/10.1007/s13555-020-00383-x
Wasel, Norman, et al. "Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)." Dermatology and therapy vol. 10,4 (2020): 663-670. doi: https://doi.org/10.1007/s13555-020-00383-x
Wasel N, Thaçi D, French LE, Conrad C, Dutronc Y, Gallo G, Berggren L, Lacour JP. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb). 2020 Aug;10(4):663-670. doi: 10.1007/s13555-020-00383-x. Epub 2020 May 15. PMID: 32415575; PMCID: PMC7367982.
Copy
Download .nbib